following a full submission:
ustekinumab (Stelara) is accepted for restricted use within NHS Scotland for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA).
Significantly more patients treated with ustekinumab achieved at least 75% improvement in their Psoriasis Area and Severity Index (PASI) score at week 12, compared with those treated with a tumour necrosis factor alpha antagonist.
Continued treatment should be restricted to patients who achieve a PASI 75 response within 16 weeks.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ustekinumab. This SMC advice is dependent upon the continuing availability of the patient access scheme in NHS Scotland.
Download detailed advice109KB (PDF)
Medicine details
- Medicine name:
- ustekinumab (Stelara)
- SMC ID:
- 572/09
- Indication:
For the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA).
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 February 2010
NOTE: Janssen-Cilag has withdrawn the Patient Access Scheme for ustekinumab (Stelara) following the launch of a 90mg pre-filled syringe on 27 October, 2015. However, the SMC advice remains valid as the cost of the 90mg dose is unchanged.